[1]覃 辉 梁明坤 张永全 陆 晖 谭文澜.rtPA 联合药物治疗急性缺血性卒中的应用[J].大众科技,2018,20(08):86-89.
 Application of rtPA Combined with Other Drugs in the Treatment of Acute Ischemic Stroke[J].Popular Science & Technology,2018,20(08):86-89.
点击复制

rtPA 联合药物治疗急性缺血性卒中的应用()
分享到:

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
20
期数:
2018年08期
页码:
86-89
栏目:
医药与卫生
出版日期:
2018-08-20

文章信息/Info

Title:
Application of rtPA Combined with Other Drugs in the Treatment of Acute Ischemic Stroke
作者:
覃 辉 梁明坤 张永全 陆 晖 谭文澜
(广西中医药大学附属瑞康医院,广西 南宁 530011)
关键词:
rtPA溶栓急性缺血性卒中联合治疗
Keywords:
rtPA thrombolytic acute ischemic stroke combination therapy
文献标志码:
A
摘要:
急性缺血性卒中(AIS)已成为老年人主要的致残及死亡原因之一,具有起病急、病死率高、神经功能恢复缓慢的特征。而超早期重组织型纤溶酶原激活剂(rtPA)溶栓治疗已经成为AIS 的一个标准治疗方法。但溶栓治疗容易出现一系列并发症,限制了其在临床治疗中的应用。文章就rtPA 联合其他药物治疗AIS 进行综述,为临床治疗AIS 提供参考。
Abstract:
Acute ischemic stroke (AIS) has become one of the main causes of disability and death in the elderly. It has the characteristics of acute onset, high mortality and slow recovery of nerve function. The ultra-early recombinant tissue plasminogen activator (rtPA) thrombolytic therapy has become a standard treatment for AIS. However, thrombolytic therapy is prone to a series of complications, which limits its application in clinical treatment. This article reviews the treatment of AIS with rtPA therapy in combination with other drugs, which provides a reference for the clinic treatment of AIS.

参考文献/References:

[1] Grotta J C,Welch K M,Fagan S C,et al.Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial[J]. Stroke,2001,32(3):661-668. [2] Zinkstok S M,Roos Y B.Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke:a randomised controlled trial[J].The Lancet,2012,380(9843): 731-737. [3] Ibrahim M M,Sebastian J,Hussain M,et al. Does current oral antiplatelet agent or subtherapeutic anticoagulation use have an effect on tissue-plasminogen-activator-mediated recanalization rate in patients with acute ischemic stroke [J].Cerebrovascular Diseases,2010,30(5):508-513. [4] ?aňák D, Kuliha M,Herzig R,et al.Prior use of antiplatelet therapy can be associated with a higher chance for early recanalization of the occluded middle cerebral artery in acute stroke patients treated with intravenous thrombolysis [J].European neurology,2012,67(1):52-56. [5] Diedler J,Ahmed N,Sykora M,et al.Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset[J].Stroke,2010,41(2): 288-294. [6] Adams H P,Del Zoppo G,Alberts M J,et al.Guidelines for the early management of adults with ischemic stroke[J]. Circulation,2007,15(20):e478-e534. [7] Prabhakaran S,Rivolta J,Vieira J R,et al.Symptomatic intracerebral hemorrhage among eligible warfarin-treated patients receiving intravenous tissue plasminogen activator for acute ischemic stroke[J].Archives of neurology,2010, 67(5):559-563. [8] Barreto A D,Ford G A,Shen L,et al.Randomized, multicenter trial of ARTSS-2(argatroban with recombinant tissue plasminogen Activator for Acute Stroke)[J].Stroke, 2017,48(6):1608-1616. [9] Chan P H.Reactive oxygen radicals in signaling and damage in the ischemic brain[J].Journal of Cerebral Blood Flow & Metabolism,2001,21(1):2-14. [10] Maier C M,Hsieh L,Crandall T,et al.Evaluating therapeutic targets for reperfusion-related brain hemorrhage[J].Annals of neurology,2006,59(6):929-938. [11] Lee B J,Egi Y,van Leyen K,et al.Edaravone,a free radical scavenger,protects components of the neurovascular unit against oxidative stress in vitro[J].Brain research,2010, 1307:22-27. [12] Kano T,Harada T,Katayama Y.Attenuation of extravasation of tissue plasminogen activator by the free radical scavenger,edaravone: evaluation in a rat thromboembolic stroke model[J].Neurological research,2005,27(5):499-502. [13] Yamashita T,Kamiya T,Deguchi K,et al.Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain[J].Journal of Cerebral Blood Flow & Metabolism,2009,29(4):715-725. [14] Kimura K,Aoki J,Sakamoto Y,et al.Administration of edaravone,a free radical scavenger,during t-PA infusion can enhance early recanalization in acute stroke patients-a preliminary study[J].Journal of the neurological sciences, 2012,313(1):132-136. [15] Endres M.Statins and stroke[J].Journal of Cerebral Blood Flow & Metabolism:Official Journal of the International Society of Cerebral Blood Flow & Metabolism,2005,25(9): 1093-1110. [16] Laufs U,Gertz K, Huang P,et al.Atorvastatin upregulates type III nitric oxide synthase in thrombocytes,decreases platelet activation,and protects from cerebral ischemia in normocholesterolemic mice[J].Stroke,2000,31(10):2442-2449. [17] Liu X S,Zhang Z G,Zhang L,et al.Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating - 89 - coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection[J]. Journal of Cerebral Blood Flow & Metabolism,2006,26(6): 787-796. [18] Stüve O,Youssef S,Steinman L,et al.Statins as potential therapeutic agents in neuroinflammatory disorders[J]. Current opinion in neurology,2003,16(3):393-401. [19] Zhang L,Zhang Z G,Ding G L,et al.Multitargeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat[J].Circulation,2005,112(22):3486-3494. [20] Koh K K,Son J W,Ahn J Y,et al.Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease[J].Arteriosclerosis Thrombosis & Vascular biology, 2002,22(9):e19-e23. [21] Zhang L,Chopp M,Jia L,et al.Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats[J].Journal of cerebral blood flow & metabolism,2009,29(11):1816-1824. [22] Montaner J,Alvarez-Sabin J,Molina CA,et al.Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke[J].Stroke,2001; 32:2762-2767. [23] Adibhatla R M,Hatcher J F.Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke:therapeutic strategies[J].CNS & Neurological Disorders- Drug Targets,2008,7(3):243-253. [24] Machado L S,Sazonova I Y,Kozak A,et al.Minocycline and tissue-type plasminogen activator for stroke[J].Stroke, 2009,40(9):3028-3033. [25] Rosenberg GA,Yang Y.Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia[J].Neurosurgical focus,2007,22(5):1-9. [26] Zhao B Q,Wang S,Hahn-Young K I M,et al.Role of matrix metalloproteinases in delayed cortical responses after stroke[J].Nature Medicine,2006,12(4):441-445. [27] Sumii T,Lo E H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats[J].Stroke,2002,33(3):831- 836. [28] Yenari M A,Xu L,Tang X N,et al.Microglia potentiate damage to blood–brain barrier constituents[J].Stroke, 2006,37(4):1087-1093. [29] Sutton T A,Kelly K J,Mang H E,et al.Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury[J].American Journal of Physiology-Renal Physiology, 2005,288(1):F91-F97. [30] Murata Y,Rosell A,Scannevin R H,et al.Extension of the thrombolytic time window with minocycline in experimental stroke[J].Stroke,2008,39(12):3372-3377. [31] Polavarapu R,Gongora M C,Yi H,et al.Tissue-type plasminogen activator–mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit[J].Blood,2007, 109(8):3270-3278. [32] Zhao B Q,Tejima E,Lo E H.Neurovascular proteases in brain injury,hemorrhage and remodeling after stroke[J].Stroke, 2007,38(2):748-752. [33] Yepes M,Sandkvist M,Wong M K K,et al.Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis[J].Blood,2000,96(2):569-576. [34] 陈立云,曾进胜,李常新,等.rt-PA 应用后 MMP-2,MMP-9表达的改变及Neuroserpin 的影响[J].中国神经精神疾病杂志,2003,29(4):258-261. [35] 江涛,刘金民,方晓磊.中医药干预急性脑梗死溶栓疗效的 Meta 分析[J].中医药临床杂志,2006,18(4):328-330.

相似文献/References:

[1]陶清芬 徐家旋.急性心肌梗死临床治疗的研究进展[J].大众科技,2022,24(07):80.
 Advances in Clinical Treatment of Acute Myocardial Infarction[J].Popular Science & Technology,2022,24(08):80.

备注/Memo

备注/Memo:
【收稿日期】2018-06-11 【作者简介】覃辉(1980-),男(壮族),广西忻城人,广西中医药大学附属瑞康医院主治医师,研究生,研究方向为脑血管疾病及痴呆。
更新日期/Last Update: 2018-09-06